A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors

NCT05860374 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Sarcoma
Carcinoma
Breast Cancer
Pancreatic Cancer
Colorectal Cancer
Gastric Cancer
Liver Cancer
Lung Cancer
Gynecologic Cancer

Interventions

DRUG: Recombinant oncolytic herpes simplex virus type 1 (R130)

Sponsor

Shanghai Yunying Medical Technology

Collaborators

[object Object]